top of page
Home
Contact
Research
Basilea
About
Services
Partners
Sign up
Blog
Â
Use tab to navigate through the menu items.
All Posts
Search
Brian White
Jul 26, 2022
Diurnal Group - Trading update ahead of R&D Day
Brian White
Jun 28, 2022
Basilea - Positive Phase 3 results
Brian White
Jun 27, 2022
Basilea - New positioning apparent
Brian White
Jun 17, 2022
Basilea - New territory growth
Andrew Keith
Jun 7, 2022
Basilea - The prospects for anti-infectives
Brian White
Apr 27, 2022
Basilea - Boosting the anti-fungal franchise
Brian White
Apr 25, 2022
Diurnal Group - Efmody set for Swiss launch with EffRx
Brian White
Apr 20, 2022
Diurnal Group - European commercial roll-out continues
Andrew Keith
Apr 1, 2022
Diurnal Group - SMC decision, financial results and outlook
Brian White
Mar 30, 2022
Diurnal Group - Commercial rollout continues
Andrew Keith
Mar 10, 2022
Basilea - Refocusing on anti-infectives
Brian White
Mar 8, 2022
Diurnal Group - SMC decision another hurdle to jump
Brian White
Feb 15, 2022
Basilea - Strategic repositioning
Andrew Keith
Feb 14, 2022
Diurnal Group - The AI and TRT opportunities
Brian White
Feb 10, 2022
Diurnal Group - Efmody moving into larger AI disorder
Brian White
Jan 26, 2022
Diurnal Group - Trading update ahead of R&D day
Andrew Keith
Jan 24, 2022
Basilea - Phase 2 data on derazantinib at ASCO
Brian White
Jan 13, 2022
Basilea - Fleshing out the Chinese Cresemba franchise
Brian White
Jan 11, 2022
Basilea - ERADICATE enrolment completed
Brian White
Jan 11, 2022
Diurnal business update - much to look forward to
1
2
3
4
5
bottom of page